PeptideDB

BI-1935 940954-41-6

BI-1935 940954-41-6

CAS No.: 940954-41-6

BI-1935 is a potent inhibitor of soluble epoxide hydrolase (sEH). BI-1935 may be used in cardiovascular disease study.
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

BI-1935 is a potent inhibitor of soluble epoxide hydrolase (sEH). BI-1935 may be used in cardiovascular disease study.

Physicochemical Properties


Molecular Formula C24H21F3N6O3
Molecular Weight 498.457154989243
Exact Mass 498.162
CAS # 940954-41-6
PubChem CID 57861407
Appearance Off-white to light yellow solid powder
LogP 1.9
Hydrogen Bond Donor Count 1
Hydrogen Bond Acceptor Count 9
Rotatable Bond Count 8
Heavy Atom Count 36
Complexity 851
Defined Atom Stereocenter Count 0
SMILES

FC(C1=CC(C2C=NC=CC=2)=NN1C1=CN=C(C=C1)NC(C1C=CC(N(C=1)CCOCC)=O)=O)(F)F

InChi Key KMESAVNRPDKZCQ-UHFFFAOYSA-N
InChi Code

InChI=1S/C24H21F3N6O3/c1-2-36-11-10-32-15-17(5-8-22(32)34)23(35)30-21-7-6-18(14-29-21)33-20(24(25,26)27)12-19(31-33)16-4-3-9-28-13-16/h3-9,12-15H,2,10-11H2,1H3,(H,29,30,35)
Chemical Name

1-(2-ethoxyethyl)-6-oxo-N-[5-[3-pyridin-3-yl-5-(trifluoromethyl)pyrazol-1-yl]pyridin-2-yl]pyridine-3-carboxamide
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


References

[1]. Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors. WO2007067836A2.


Solubility Data


Solubility (In Vitro) DMSO : ~100 mg/mL (~200.62 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.5 mg/mL (5.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (5.02 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 3: ≥ 2.5 mg/mL (5.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.0062 mL 10.0309 mL 20.0618 mL
5 mM 0.4012 mL 2.0062 mL 4.0124 mL
10 mM 0.2006 mL 1.0031 mL 2.0062 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.